Literature DB >> 24890848

Re: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

D Diwakar1, T Choi1, T H Tawbi1, J M Kirkwood2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24890848      PMCID： PMC4375417          DOI： 10.1093/annonc/mdu196

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

Authors:  Laura J Vella; Anupama Pasam; Nektaria Dimopoulos; Miles Andrews; Ashley Knights; Anne-Laure Puaux; Jamila Louahed; Weisan Chen; Katherine Woods; Jonathan S Cebon
Journal:  Cancer Immunol Res       Date:  2014-01-17       Impact factor: 11.151

2.  Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

Authors:  B Schilling; W Sondermann; F Zhao; K G Griewank; E Livingstone; A Sucker; H Zelba; B Weide; U Trefzer; T Wilhelm; C Loquai; C Berking; J Hassel; K C Kähler; J Utikal; P Al Ghazal; R Gutzmer; S M Goldinger; L Zimmer; A Paschen; U Hillen; D Schadendorf
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

3.  The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.

Authors:  Begoña Comin-Anduix; Thinle Chodon; Hooman Sazegar; Douglas Matsunaga; Stephen Mock; Jason Jalil; Helena Escuin-Ordinas; Bartosz Chmielowski; Richard C Koya; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

4.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.